North America Drives Cold Plasma Market Growth with Increased R

In 2024, the cold plasma market generated a revenue of USD 2,312.8 million and is expected to grow at a CAGR of 15.8% from 2024 to 2030. By 2030, the market is projected to reach USD 5,568 million, driven by the various benefits of cold plasma technology, particularly in wound healing, along with continuous advancements in the field.

In 2022, the polymer and plastic segment accounted for over 32% of the market share, largely due to the demand for strong surface adhesion in plastic and polymer packaging. This is essential for enhancing mechanical performance and extending the lifespan of plastic components.

Given the increasing adoption of cold plasma in the polymer and plastic industry, several leading companies have begun offering systems and devices that allow for its broader utilization. Atmospheric cold plasma held the largest share of the cold plasma market, owing to its wide application across various sectors.

Download free report sample at: https://www.psmarketresearch.com/market-analysis/cold-plasma-market/report-sample

For example, research on cold plasma technology has shown promising results in treating eczema. A team from the Institute of Plasma Physics, Chinese Academy of Sciences, conducted experiments with animal models, revealing the potential for cold plasma to treat eczema without harmful side effects. It’s important to note that atopic dermatitis, commonly known as eczema, has no cure, and current treatment focuses on symptom management through proper care.

In the next few years, the wound healing segment is expected to experience the highest revenue CAGR of 15.4%, largely due to the growing use of cold plasma to accelerate wound healing. This process relies on creating a high-voltage discharge between a device called the plasmodesma and the skin.

North America dominated the market in 2022, with a 44% share, and is expected to maintain its growth due to increased healthcare spending and research activities.

For instance, in March 2022, the Jerome Canady Research Institute for Advanced Biological and Technological Sciences (JCRI-ABTS) released findings on how a combination of Canady Helios cold plasma and anti-BCL2A1 treatments could benefit patients with breast cancer and other solid tumors. Additionally, the U.S. government has increased its cancer research funding, with the Consolidated Appropriations Act of 2023 allocating USD 7.2 billion to the National Cancer Institute (NCI), including USD 216 million for the Cancer Moonshot program.

About P&S Intelligence

 

P&S Intelligence offers custom and syndicated market research and consulting services to clients across the globe. Our team of young and dynamic researchers, guided by mentors with years of experience, create data-rich reports tailored to the needs of MNCs as well as startups and SMEs. We remain in a perennial quest to offer exhaustive insights into every aspect of the market, allowing businesses of all sizes to seize even the smallest of opportunities and tackle even the biggest of challenges.

 

Contact:
Chandra Mohan
AVP – Business Development
Phone: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com